14.6-month median PFS with LENVIMA + everolimus vs 5.5 months with everolimus alone (primary endpoint)1
- Number of events: 26 (51%) with LENVIMA + everolimus and 37 (74%) with everolimus
13.6-month median OS was achieved with LENVIMA vs 12.3 months with sorafenib (primary endpoint)1
- Number of events: 351 (73%) with LENVIMA and 350 (74%) with sorafenib
18.3-month median PFS was observed with LENVIMA vs 3.6 months with placebo (primary endpoint)1
- Number of events: 107 (41%) with LENVIMA and 113 (86%) with placebo
Reference: 1. LENVIMA [package insert]. Woodcliff Lake, NJ: Eisai Inc.; 2020.
The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider.
All decisions regarding patient care must be made with a health care professional, considering the unique characteristics of the patient.
This site is intended for U.S. health care providers only. The product discussed herein may have different product labeling in different countries.
To report suspected adverse reactions, contact Eisai Inc. at 1-888-274-2378 or the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch.
© 2020 Eisai Inc. All rights reserved. LENV-US3921 us.eisai.com